|
|
2010 |
- Hexvix® approved in the US under the tradename Cysview™
- Lumacan® licensed to Salix Pharmaceuticals Inc
|
|
|
2009 |
- All rights to Metvix®/Aktilite® sold to Galderma |
|
|
2008 |
- Metvix®/Aktilite® approved in the US
|
|
|
2007 |
- Submitted application (sNDA) for approval of Aktilite® in the US |
| |
2006 |
- Signed licensing agreement with GE Healthcare for Hexvix®
- Hexvix® launched in Europe |
| |
2005 |
- Hexvix® approved in all EU/EEA countries
- Hexvix® launched in the Nordic region
- NDA filed for Hexvix® in the US |
| |
2004 |
- First marketing authorisation obtained for Hexvix® |
| |
2003 |
- Galderma's first Metvix launch |
| |
2002 |
- First marketing authorisation application filed for Hexvix® |
| |
2001 |
- First marketing authorisation obtained for Metvix
- Metvix and Aktilite marketed for the first time
- Licensing agreement for Metvix signed with Galderma |
| |
2000 |
- First marketing authorisation application filed for Metvix
- Listing of the company's share on the Oslo Stock Exchange
- Start of Hexvix® clinical studies
|
| |
1997 |
- Recruited first full-time employee
- Start of formal clinical studies for Metvix |